ImmunityBio, a biotech company focused on immune therapies, experienced a notable drop in stock price, finishing at $6.45, down 12.13% amid profit-taking and the release of new glioblastoma survival data. Despite this decline, the stock remains significantly up, boasting a 63.29% increase over the past five days and an impressive 207.14% surge in the last month. The trading volume was particularly high, with 74.6 million shares exchanged, more than double the three-month average of 22.1 million shares.
The company’s challenging history, having gone public in 2015 and subsequently losing 83% of its value, contrasts sharply with its recent performance. Major catalysts for this growth include a strategic agreement with the FDA regarding the resubmission of its Anktiva application for bladder cancer treatment and recent regulatory approval from the Saudi FDA for the same drug.
Market dynamics reflected relative stability overall, with the S&P 500 inching up by 0.03% and the Nasdaq Composite posting a 0.28% increase. Other biotech stocks like Merck and BioNTech also saw minor losses, reflecting the ongoing volatility in the industry, particularly surrounding oncology and vaccine pipelines.
Investors appear encouraged by ImmunityBio’s recent developments. Last week, the firm reported full-year earnings that surpassed analyst expectations, achieving a net profit of $113 million — a nearly 700% increase compared to the previous year. In addition, the latest data announced today indicated that 19 out of 23 patients with progressive glioblastoma receiving Anktiva remain alive, although the median overall survival has yet to be established.
Several analysts have responded positively, including H.C. Wainwright, which has raised its price targets for the stock. Moreover, significant exits from short positions have further propelled the cancer drugmaker’s performance, with reports indicating nearly $492 million in paper losses for short sellers.
As the market continues to react to ImmunityBio’s developments and broader biotech trends, investors remain vigilant for opportunities within an industry characterized by rapid changes and high volatility.
